Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia

被引:0
|
作者
Yun, Ji Hyun [1 ]
Chang, Euijin [2 ]
Bae, Seongman [2 ,3 ]
Jung, Jiwon [2 ]
Kim, Min Jae [2 ]
Chong, Yong Pil [2 ]
Kim, Sung-Han [2 ]
Choi, Sang-Ho [2 ]
Lee, Sang-Oh [2 ]
Kim, Yang Soo [2 ,3 ]
机构
[1] Konkuk Univ, Sch Med, Dept Internal Med, Div Infect Dis,Med Ctr, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Div Infect Dis, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Ctr Antimicrobial Resistance & Microbial Genet, Seoul, South Korea
来源
MICROBIOLOGY SPECTRUM | 2024年 / 12卷 / 08期
关键词
hVISA; vancomycin; treatment failure; risk factors; age; severity; minimal inhibitory concentration; MINIMUM INHIBITORY CONCENTRATIONS; METHICILLIN-RESISTANT; CLINICAL-FEATURES; INFECTIONS; STRAINS; HETERORESISTANCE; SUSCEPTIBILITY; DEFINITION; CRITERIA;
D O I
10.1128/spectrum.00333-24
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infection is increasing and is associated with vancomycin treatment failures. However, studies investigating the risk factors for treatment failure in hVISA infection are limited. Patients with hVISA bacteremia treated with vancomycin over 7 days between August 2008 and June 2020 were enrolled in this study. Clinical and microbiological characteristics were compared between vancomycin treatment failure and success groups to identify the risk factors for vancomycin treatment failure. Among the 180 patients with hVISA bacteremia, 102 patients treated with vancomycin over 7 days were included. Vancomycin treatment failed in 80 (78%) patients. Patients in the vancomycin treatment failure group were older (P < 0.001) and more frequently had solid cancer (P = 0.04) than those in the vancomycin treatment success group. Solid organ transplantation (SOT) was more frequent (P < 0.001) in the vancomycin treatment success group. The Charlson comorbidity index (P = 0.01) and Acute Physiology and Chronic Health Evaluation II scores (P < 0.001) were higher in the vancomycin treatment failure group. In multivariate analysis, independent risk factors for vancomycin treatment failure were old age and severity of bacteremia. SOT and vancomycin minimal inhibitory concentration (MIC) <= 1.0 mg/L using the broth microdilution (BMD) method were associated with successful vancomycin treatment. Old age and infection severity were independent risk factors for vancomycin treatment failure. Vancomycin MIC using the BMD method is an important risk factor for vancomycin treatment failure, and its use should be considered in hVISA bacteremia. IMPORTANCE In this study, we assessed the clinical and microbiological characteristics of heterogeneous vancomycin-intermediated Staphylococcus aureus (hVISA) bacteremia and identified risk factors for vancomycin treatment failure. We found that advanced age and severity of infection were independent risk factors for vancomycin treatment failure. On the other hand, solid organ transplantation and a low vancomycin minimal inhibitory concentration were associated with successful vancomycin treatment. This study highlights the importance of vancomycin minimal inhibitory concentration in hVISA bacteremia.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Failure of Vancomycin Continuous Infusion against Experimental Endocarditis Due to Vancomycin-Intermediate Staphylococcus aureus
    Entenza, J. M.
    Veloso, T. R.
    Vouillamoz, J.
    Giddey, M.
    Moreillon, P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (01) : 385 - 387
  • [22] Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore
    Fong, R. K. C.
    Low, J.
    Koh, T. H.
    Kurup, A.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2009, 28 (08) : 983 - 987
  • [23] Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore
    R. K. C. Fong
    J. Low
    T. H. Koh
    A. Kurup
    European Journal of Clinical Microbiology & Infectious Diseases, 2009, 28
  • [24] Continuous Infusion May Improve the Efficacy of Vancomycin in Treatment of Experimental Endocarditis Due to Heterogeneous Vancomycin-Intermediate Staphylococcus aureus
    Entenza, J. M.
    Veloso, T. R.
    Vouillamoz, J.
    Giddey, M.
    Moreillon, P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (09) : 4496 - 4497
  • [25] Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus
    Rose, Warren E.
    Knier, Ryan M.
    Hutson, Paul R.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (10) : 2149 - 2154
  • [26] Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance
    Neoh, Hui-Min
    Cui, Longzhu
    Yuzawa, Harumi
    Takeuchi, Fumihiko
    Matsuo, Miki
    Hiramatsu, Keiichi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (01) : 45 - 53
  • [27] A Novel δ-Hemolysis Screening Method for Detecting Heteroresistant Vancomycin-Intermediate Staphylococcus aureus and Vancomycin-Intermediate S-aureus
    Cafiso, V.
    Bertuccio, T.
    Spina, D.
    Purrello, S.
    Blandino, G.
    Stefani, Stefania
    JOURNAL OF CLINICAL MICROBIOLOGY, 2012, 50 (05) : 1742 - 1744
  • [28] Cell wall thickness and the molecular mechanism of heterogeneous vancomycin-intermediate Staphylococcus aureus
    Cui, J.
    Zhang, H.
    Mo, Z.
    Yu, M.
    Liang, Z.
    LETTERS IN APPLIED MICROBIOLOGY, 2021, 72 (05) : 604 - 609
  • [29] Draft Genome Sequences of Vancomycin-Susceptible Staphylococcus aureus Related to Heterogeneous Vancomycin-Intermediate S. aureus
    Ramaraj, Thiruvarangan
    Matyi, Stephanie A.
    Sundararajan, Anitha
    Lindquist, Ingrid E.
    Devitt, Nicolas P.
    Schilkey, Faye D.
    Lamichhane-Khadka, Reena
    Hoyt, Peter R.
    Mudge, Joann
    Gustafson, John E.
    GENOME ANNOUNCEMENTS, 2014, 2 (05)
  • [30] DIFFERENTIAL INFLAMMATORY RESPONSES IN MACROPHAGES BY VANCOMYCIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS AND VANCOMYCIN-INTERMEDIATE STAPHYLOCOCCUS AUREUS
    Lee, H. -S.
    Kuo, T. -Y.
    INFLAMMATION RESEARCH, 2011, 60 : 159 - 159